最新ニュース Smurfit WestRock (NYSE:SW) 株価情報

Smurfit WestRock

Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.

Smurfit WestRock PLC

SRISAWAD CRP PCL FRGN SHS by Srisawad Corp Pub Co Ltd.

Stran & Co Inc

Amplify ETF Trust Amplify BlackSwan Growth & Treasury Core ETF

TrustSwap

Swash

SHOCKWAVE MED INC

Smith & Wesson Brands, Inc. - Common Stock

Smith & Wesson Brands Inc

SOUTHWEST CASINO CORP by Southwest Casino Corp.

Southwest Casino Corp

SUNWAY CONSTR GRP by SUNWAY CONSTR GROUP BHD

SWCC Corp

SOFTWARE AG by Software AG

Swedbank AB

Swedencare AB

SKYWORTH GROUP LTD by Skyworth Group Limited

Skyworth Group Ltd

SKYWORTH GRP LTD UNSP/ADR by Skyworth Group Limited

SWEAT - United States Dollar

SWEEGEN INC by SweeGen, Inc.

Swell - United States Dollar

Swell Ethereum - United States Dollar

SwiftCoin - United States Dollar

SWATCH GROUP AG NEW ORD by Swatch Group AG

The Swatch Group AG

SWATCH GROUP AG UNSP/ADR by Swatch Group AG

SAWAI GROUP HLDGS CO LTD by SAWAI GROUP HLDGS CO LTD.

Sawai Group Holdings Co Ltd

STAR WEALTH GROUP INC by Star Wealth Group Inc.

SUMITOMO WAREHOUSE CO by Sumitomo Warehouse Co. Ltd.

Sumitomo Warehouse Co Ltd

SOLARWINDS INC COM

Latham Group Inc

Solowin Holdings - Class A Ordinary Share

Solowin Holdings Ltd

Swingby

Southwest Iowa Renewable Energy LLC Units Series -A-

Southwest Iowa Renewable Energy LLC

SEKUR PRIVATE DATA LTD by SEKUR PRIVATE DATA LTD.

Sekur Private Data Ltd

Stanley Black & Decker, Inc. Common Stock

Stanley Black & Decker Inc

SWK Holdings Corp

SWK Holdings Corporation - 9.00% Senior Notes due 2027

Skyworks Solutions Inc

SILVER WOLF EXPLORATION by Silver Wolf Exploration Ltd.

Silver Wolf Exploration Ltd

Swedish Match AB ADR

STARWIN MEDIA HLDGS INC by Starwin Media Holdings, Inc.

Starwin Media Holdings Inc

Swarmio Media Holdings Inc

Southwestern Energy Company COM

Miratap Inc

EDM Resources Inc

SWSTRN MEDICAL SLTNS INC by Southwestern Medical Solutions, Inc.

Southwestern Medical Solutions Inc

SWEDISH ORPHAN BIO U/ADR by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOFTWAREONE HLDG AG by SOFTWAREONE HLDG AG

SoftwareONE Holding AG

Swop

SWP Growth & Income ETF

Kava Swap

SWIRE PROPERTIES LTD ORD by Swire Properties Ltd.

Swire Properties Ltd

SWIRE PROPERTIS UNSP/ADR by Swire Properties Ltd.

SWISS PRIME SITE AG U/ADR by Swiss Prime Site AG

Swiss Prime Site AG

SWOOP HOLDINGS LTD by Swoop Holdings Ltd.

Swoop Holdings Ltd

SWISS PRIME SITE AG by Swiss Prime Site AG

SHOWA PAXXS CORP TOKYO by SHOWA PAXXS CORP

SWISSQUOTE GROUP HOLDING by Swissquote Group Holding AG

Swissquote Group Holding SA

SWIRE PACIFIC LTD A by Swire Pacific Ltd.

Swire Pacific Ltd

SWIRE PAC LTD A S/ADR by Swire Pacific Ltd.

SWIRE PACIFIC LTD B ORD by Swire Pacific Ltd.

SWIRE PACIFIC LTD B S/ADR by Swire Pacific Ltd.

SHIBUSAW LOGISTICS CORP by SHIBUSAW LOGISTICS CORP

Shibusawa Logistics Corp

SEAWRIGHT HOLDINGS INC by Seawright Holdings, Inc.

Seawright Holdings Inc

U-Swirl Inc

AppSwarm Corp

Swerve

SWISS LIFE HOLDING AG by Swiss Life Holding

Swiss Life Holding AG

CLEAN ENGY SPCL SITUTINS by Clean Energy Special Situations Corp.

Clean Energy Special Situations Corp

SWISS WTR DECAF COFFEE by Swiss Wtr Decaffinated Coffee Inc.

Swiss Water Decaffeinated Coffee Inc

Clean Energy Special Situations Corp Units (1 Ord & 1/2 War)

Clean Energy Special Situations Corp Warrants (01/12/2027)

Carbon

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Swvl Holdings Corp

SIMON WORLDWIDE INC by Simon Worldwide, Inc.

Simon Worldwide Inc

Southwest Gas Holdings, Inc. Common Stock (DE)

Southwest Gas Holdings Inc

Sanoma Oyj

STORNOWAY DIAMOND CORP by Stornoway Diamond Corp.

Stornoway Diamond Corp

Total Return Securities Fund Common Stock

Swiss Helvetia Fund Inc

Swisscom AG

SCHWEIZERISCHE NATLBANK by Schweizerische Nationalbank

Schweizerische Nationalbank

HC Wainwright &amp; Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) with a Buy and maintains $20 price target.

News

Price Target

Reiteration

Analyst Ratings

SLDB

HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $20 Price Target

Armada Acquisition Corp. II (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACIU#NASDAQ">AACIU</a>) (the "Company") announced today that, commencing June 24, 2025, holders of the 23,000,000 units sold in the Company's initial public offering may elect to separately trade shares of the Company's Class A ordinary shares and warrants included in the units. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Stock Market LLC ("Nasdaq") under the symbols "AACI" and "AACIW", respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade on Nasdaq under the symbol "AACIU." Holders of units will need to have their brokers contact Continental Stock Transfer &amp; Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants.
The units were initially offered by the Company in an underwritten offering. Cohen &amp; Company Capital Markets, a division of J.V.B. Financial Group LLC, acted as lead book-runner, and Northland Capital Markets acted as joint book-runner for the offering. A registration statement relating to the securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on May 20, 2025.

IPOs

AACIU

Armada Acquisition Corp. II to Begin Trading Shares and Warrants Separately Starting June 24

WIIM

CERO

CERo Therapeutics shares are trading higher after the company received FDA Orphan Drug Designation for CER-1236 for the treatment of acute myeloid leukemia.

Biotech

Health Care

General

MLYS

Mineralys Therapeutics Announced Topline Data From Its Phase 2 Explore-CKD Trial Of 25 mg Of Lorundrostat For Hypertension And Comorbid CKD, The Trial Met The Primary Endpoint And Demonstrated Clinically Meaningful Reductions In Both Systolic Automated Office Blood Pressure And Urine Albumin-to-creatinine Ratio, And Demonstrated A Favorable Safety And Tolerability Profile

Retailers drive increased focus on food safety and traceability as 40 new suppliers enter the queue to join the ReposiTrak Traceability Network
ReposiTrak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 40 retail food suppliers to the queue of companies joining the ReposiTrak Traceability Network&#xAE; (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.

TRAK

ReposiTrak Adds 40 Retail Food Suppliers To Queue Of Companies Joining ReposiTrak Traceability Network

VTYX

Ventyx Biosciences Announces Topline Results From Phase 2a Study Of VTX3232 In Early-Stage Parkinson's Disease; Says VTX3232 Resulted In Reductions In NLRP3-Related Biomarkers In CSF And Plasma

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54277068&amp;newsitemid=20250617270939&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=b6dfd00834f3e12c6b934a69954d0400">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer, will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Eno and Cruickshank will also host virtual one-on-one meetings with institutional investors during the event.
iAccess Alpha Virtual Summer Conference Dates: June 24-25, 2025 Location: Virtual Format: Presentation and Virtual 1x1 Meetings Attendees: Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer Presentation Time: 2:00 p.m. Eastern Time on June 24 Webcast: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.webcaster4.com%2FWebcast%2FPage%2F3118%2F52509&amp;esheet=54277068&amp;newsitemid=20250617270939&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.webcaster4.com%2FWebcast%2FPage%2F3118%2F52509&amp;index=2&amp;md5=699062b2a9fa4b3694ae594aa4367234">https://www.webcaster4.com/Webcast/Page/3118/52509</a>
A webcast of the presentation will also be available under the Events section of the Company's investor relations website linked <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.heartbeam.com%2F&amp;esheet=54277068&amp;newsitemid=20250617270939&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=6fe182e043861732ab79a99468bbef56">here</a>.
To schedule a one-on-one investor meeting with HeartBeam management, please contact your iAccess Alpha conference representative or email your request to <a href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> or call Chris Tyson at (949) 491-8235.

BEAT

HeartBeam to Share Cardiac Tech Vision With Investors at iAccess Alpha Summer Conference

Sonoco Names Paul Joachimczyk Chief Financial Officer, Effective June 30, 2025

<a href="https://www.globenewswire.com/Tracker?data=UueBjGoXAbORlRjtnvH-X8SQC9F1XxK4oYRaweKDKie6rNQBRKUeNjn6HuW1kx1iCbgdD6udgg3PIR42gBxWDzMX6qxChy_EYxObLoZLr1CJDE2rpvaBUgwvJIizmq9jC9tp8u7Bn8xVdmZPy8sW3KRAJ46bx3FlL9nAll0Ym5yWf2eeaidWUfqodHzmlMHJ">Lantronix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>), a global leader in compute and connectivity IoT solutions enabling Edge AI Intelligence, today announced its collaboration with <a href="https://www.globenewswire.com/Tracker?data=PTj7n2CyngxY_fdnO8aRrjo8TnGLiipRegwMXW-X0QVFszynwxdJl77dJf2J7tk5LPNfNk-PdsVjbW93NMeEbA==">Aerora</a>, a provider of integrated NDAA-compliant propulsion, ground control and precision AI payload systems. This collaboration delivers Edge AI-driven solutions that significantly accelerate advancements in drones, robotics and surveillance applications delivered by Aerora's OEM platform for AI-Powered Visual Navigation.

LTRX

Lantronix Teams Up With Aerora to Power Smarter Drones and Robots With Edge AI Tech

<a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1079625" title="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1079625">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1079625</a>

CERo Therapeutics On Monday Received FDA Orphan Drug Designation For CER-1236 For Treatment Of Acute Myeloid Leukemia

Benchmark analyst David Williams maintains Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) with a Buy and raises the price target from $120 to $130.

Benchmark Maintains Buy on Belden, Raises Price Target to $130

GRMN

Garmin Builds Its First-Ever Bike Computer For Mountain Trails With Edge MTB's Rugged Design And 26-Hour Battery Life

China Renaissance analyst Cindy Wang initiates coverage on Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy rating and announces Price Target of $353.3.

Initiation

COIN

China Renaissance Initiates Coverage On Coinbase Global with Buy Rating, Announces Price Target of $353.3

NT219 is a novel small molecule designed to target two key oncogenic pathways: IRS1/2 (Insulin Receptor Substrates 1 and 2) and STAT3 (Signal Transducer and Activator of Transcription 3).&nbsp; NT219 induces the degradation of IRS1/2 and inhibits the phosphorylation of STAT3, thereby, blocking their respective signaling pathways. The Phase 2 study will evaluate NT219 in combination with either pembrolizumab (KEYTRUDA&#xAE;) or cetuximab, both of which are standard-of-care treatments in R/M SCCHN patients. Additionally, the study aims to evaluate potential biomarkers identified in a previous clinical study of NT219.

PPBT

Purple Biotech Initiated Phase 2 Study Evaluating NT219 In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations and manufacturing at its Israeli facility focusing on business continuity, and based on its assessment, the global availability of its products is not expected to be interrupted.
"While events in the Middle East are evolving, the operations and ongoing manufacturing of our products continue as planned," said Amir London, Kamada's Chief Executive Officer. "Although our shipments from Israel may be temporarily affected by the current closing of the Israeli airspace, our distribution centers outside Israel, as well as our partners and distributors worldwide, have sufficient level of products available, and we do not foresee shortage in meeting client demands. We are focused on our business continuity and the well-being of all our employees and will continue to closely monitor the circumstances."

KMDA

Kamada Assures Uninterrupted Drug Supply as Israeli Operations Continue Despite Middle East Tensions

Events

SKYE

Skye Bioscience To Present At American Diabetes Association's 85th Scientific Sessions On Jun. 22

Back in 1996, Microsoft CEO Bill Gates reviewed a book called Warren Buffett: The Making of an American Capitalist by Roger Lowenstein, where he shared the lessons ‘Oracle of Omaha' Berkshire Hathaway CEO Warren Buffett, taught him.
What Happened: Writing <a href="https://hbr.org/1996/01/what-i-learned-from-warren-buffett">for</a> the Harvard Business Review, Gates remembered his first meeting with Buffett in July 1991. "I was extremely skeptical when my mother suggested I take a day away from work to meet him," Gates wrote.
"What were he and I supposed to talk about, P/E ratios? I mean, spend all day with a guy who just picks stocks? Especially when there's lots of work to do? Are you kidding?" he recalled thinking.
His mother's insistence eventually pushed Gates to agree to attend the gathering Buffett was part of. "He asked good questions and told educational stories," Gates wrote. "There's nothing I like so much as learning, and I had never met anyone who thought about business in such a clear way."
As their acquaintance continued, Gates was particularly impressed by <a href="https://www.benzinga.com/general/education/25/05/45602754/warren-buffett-investment-success-3-simple-rules-to-copy-oracle-of-omaha">Buffett's investing philosophy</a>. As Buffett once wrote, "Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results." 
"Warren never makes an investment where the difference between doing it and not doing it relies on the second digit of computation," Gates explained. "He doesn't invest—take a swing of the bat—unless the opportunity appears unbelievably good."
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45940555/naval-ravikant-says-elon-musks-a-purist-recalling-why-he-likely-never-speaks-to-bill-gates">Naval Ravikant Says Elon Musk&#8217;s A &#8216;Purist&#8217; Recalling Why He Likely Never Speaks To Bill Gates</a>
Why It Matters: Buffett's habit of sticking to what he knows well, reading extensively, and saying no to distractions was influential for Gates. "He knows what he likes to do—and what he does, <a href="https://www.benzinga.com/25/04/44855242/charlie-munger-once-highlighted-how-warren-buffetts-lifelong-learning-made-berkshire-hathaways-success-possible-and-the-crucial-lesson-you-can-take-from-it">he does unbelievably well</a>," Gates observed.
One quote in particular stood out to Gates: "You should invest in a business that even a fool can run, because someday a fool will." This bit of wisdom shaped Gates's perspective on management and risk.
Buffett also challenged Gates to be more creative with his thinking, once using a set of nontransitive dice to demonstrate a counterintuitive truth in probability. "It was counterintuitive, like a lot of things in the business world."
Gates also highlighted Buffett's parenting approach: "<a href="https://www.benzinga.com/personal-finance/25/04/44889632/warren-buffetts-son-cashed-in-90k-instead-of-waiting-on-500-million-now-hes-using-buffett-bucks-to-build-his-own-dream-town-in-new-york">He wants to give his children enough money for them to do anything</a> but <a href="https://www.benzinga.com/personal-finance/25/04/44657074/warren-buffetts-kid-says-they-had-to-pull-their-own-weight-if-you-went-to-the-movies-you-never-knew-if-he-would-buy-your-ticket-or-not">not enough for them to do nothing</a>." That statement "crystallized my feelings," Gates admitted.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45938365/trumps-1000-baby-account-aligns-with-billionaire-investor-warren-buffetts-start-young-philosophy">Trump&#8217;s $1,000 Baby Account Aligns With Billionaire Investor Warren Buffett&#8217;s &#8216;Start Young&#8217; Philosophy</a></li>
</ul>
Photo courtesy: mark reinstein / Shutterstock.com

Equities

Bill Gates Once Scoffed, 'Spend All Day With A Guy Who Just Picks Stocks?'—Before Discovering That The 'Stock Picker' Had A Mastermind's Blueprint For Winning In Business

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aldeyra.com%2F&amp;esheet=54276760&amp;newsitemid=20250617568242&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=7935efc7409c924962b58b43bc4b8f61">Aldeyra Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint.
"Consistent with a number of clinical trials that suggest the potential of reproxalap to rapidly improve the symptoms of dry eye disease, we believe the clinical trial results included in the resubmission announced today are robust," stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. "Based on the lack of notable baseline differences across treatment arms and the highly statistically significant achievement of the prespecified primary endpoint in favor of reproxalap over vehicle, in conjunction with recent FDA discussions, we believe that previous concerns raised by the FDA have been addressed."
In April 2025, Aldeyra received a Complete Response Letter from the FDA that stated that potential methodological issues in a previously completed dry eye chamber trial, including a baseline difference across treatment arms, may have affected the interpretation of the results; the letter stated that an additional symptom trial would be required for resubmission. In May 2025, Aldeyra announced the achievement of the primary endpoint (P=0.002) in a Phase 3 randomized, double‑masked, vehicle‑controlled dry eye chamber trial that assessed the activity of reproxalap in reducing ocular discomfort, an FDA‑accepted symptom of dry eye disease. No notable differences in baseline scores across treatment arms were observed in the clinical trial, and no safety concerns were identified. Consistent with prior clinical trials, the most common adverse event was mild and transient instillation site discomfort, which most commonly lasted less than one minute.
The Prescription Drug User Fee Act target guidelines for NDA resubmissions include acknowledgment of acceptance for review within 30 days of submission, and completion of submission review within 6 months.

Government

Regulations

ALDX

Aldeyra Resubmits Eye Drug for FDA Review After New Trial Clears Key Hurdle in Treating Dry Eye

Stock Split

UNCY

Unicycive Therapeutics Will Implement A 1-for-10 Reverse Split, Effective On June 20, 2025

<ul>
<li>As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of&nbsp;C. difficile&nbsp;infection (CDI) recurrence through one month after EOT</li>
<li>In contrast, 2 of 14 (14%) patients treated with the standard of care, oral&nbsp;vancomycin, experienced recurrent infection within one month after EOT</li>
<li>When Phase 2b results are combined with Phase 2a results, 25 of 25 (100%)&nbsp;ibezapolstat-treated patients with CDI who had CC at EOT remained recurrence-free through 1 month after EOT; additionally, all 5 Phase 2b ibezapolstat-treated patients observed for up to 3 months following CC experienced no recurrence of infection</li>
</ul>

Comments

Smurfit WestRock

ニュース

最新ニュース Smurfit WestRock (NYSE:SW) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル